Fondaparinux as an alternative anticoagulant therapy during pregnancy by Knol, H.M. et al.
  
 University of Groningen
Fondaparinux as an alternative anticoagulant therapy during pregnancy
Knol, H.M.; Schultinge, L.; Erwich, J.J.H.M.; Meijer, K.
Published in:
JOURNAL OF THROMBOSIS AND HAEMOSTASIS
DOI:
10.1111/j.1538-7836.2010.03926.x
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2010
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Knol, H. M., Schultinge, L., Erwich, J. J. H. M., & Meijer, K. (2010). Fondaparinux as an alternative
anticoagulant therapy during pregnancy. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 8(8), 1876-
1879. https://doi.org/10.1111/j.1538-7836.2010.03926.x
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the
number of authors shown on this cover page is limited to 10 maximum.
Download date: 12-11-2019
lead to DVT or PE, and require no or different treatment [7].
Finally, we used a standardized, but not validated, question-
naire to inquire about inﬂammatory or infectious signs.
Therefore, misclassiﬁcation could have occurred. Nevertheless,
one should expect similar misclassiﬁcation in both cases and
controls.
In conclusion, this study showed that DVT was often
preceded by signs of transient inﬂammation or infection,
suggesting an association or pathogenic relationship between
venous thrombosis and an underlying inﬂammatory or infec-
tious disease.
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Hypersensitivity skin reactions are frequently seen in pregnant
patients who use low-molecular-weight heparin (LMWH) [1].
When this heparin intolerance occurs, alternative choices for
anticoagulation are limited. Hypersensitivity skin reactions
often recur when another preparation of LMWH is substituted
[1]. Danaparoid is another preparation of choice which does
not pass the placenta [2], but is not always available. Most
patients strongly wish to avoid vitamin K antagonists, even
beyond the 12th week of pregnancy, because of the association
with congenital and developmental abnormalities [3,4]. Fonda-
parinux, a synthetic selective inhibitor of activated factor X
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(FXa), is commonly used as an alternative anticoagulant in
non-pregnant patients who develop heparin intolerance.
Fondaparinux has been extensively studied for use in surgery
prophylaxis and treatment of thromboembolic diseases [5].
However, data on the use of fondaparinux in pregnancy is
limited to animal models and a few case reports [6–10].
Although it has been shown that transplacental passage can
occur resulting in low measurable FXa activity in cord blood
[11], no adverse outcomes in pregnancy have been reported in
these four women. The other six separately published cases
reported no adverse events to the mother or child [6–10]. In our
hospital, experience with fondaparinux as an alternative in
pregnant women has accumulated. The aim of the present
study was to evaluate the use and safety of fondaparinux
during pregnancy.
From 2003 until the present, we prospectively followed a
consecutive cohort of 133 women in our university hospital
who used anticoagulant therapy during their pregnancy and
puerperium. The indication for anticoagulant therapy was a
history of idiopathic, provoked or previous pregnancy-related
venous thrombo-embolism (VTE) or recurrent fetal loss.
Recurrent fetal loss was deﬁned as two or more fetal losses.
In all women thrombophilia screening was performed. Applied
assays have been described elsewhere [12]. All women were
started on a LMWH (nadroparin or tinzaparin) in early
pregnancy with a bodyweight adjusted therapeutic dosage (175
anti-Xa IU kg)1 day)1), as soon as a pregnancy test was
positive. All women were followed in a combined obstetric/
coagulation clinic and seen by a thrombosis specialist every
2 months until 6 weeks post-partum. Anti-FXa levels were not
routinely monitored in maternal and cord blood and doses of
LMWH were not adjusted for increasing bodyweight or
increasing renal clearance. If hypersensitivity skin reactions
developed, we either switched once to another preparation
(tinzaparin or nadroparin), acenocoumarol or started fonda-
parinux 2.5 mg subcutaneously twice daily. Fondaparinux
7.5 mg once daily (therapeutic dosage) is not available in the
Netherlands, and we wished to avoid thrice daily injections.
The women had no standard planned induction with with-
holding of fondaparinux, but anticoagulation was stopped at
the start of spontaneous labor and restarted 4–8 h after
delivery (when blood loss was normal) and stopped 6 weeks
post-partum. Data were systematically collected by the throm-
bosis physicians during pregnancy on an indication for
anticoagulant therapy; start date of LMWH; trimester of
switching to another LMWH, vitamin K antagonist or
fondaparinux; bleeding and thrombo-embolic complications
during pregnancy, delivery and post-partum period; side effects
of anticoagulants; gestational age of delivery; blood loss during
delivery; birth weight and neonatal bleeding/congenital abnor-
malities. National legislation and the ethical committee of our
institution approve this type of studies without the need for
review of the protocol. All women were informed about the
risks of the off label use of fondaparinux during pregnancy and
agreed with it. In this letter, we report on the 12 out of 190
pregnancies in 133 women in whom fondaparinux was used.
We treated 10 patients with fondaparinux during pregnancy
and the puerperium in our institution, two of them during two
pregnancies. Their median age was 30 years (range 26–
34 years). Six of them had a history of VTE during combined
oral contraceptive use, three patients had a history of an
idiopathic VTE and one patient had a history of recurrent fetal
loss. None of the patients had a history of allergy to LMWH.
Eight patients were switched to fondaparinux in the 2nd

























1 32 PE during COC PS def type I/hetzg
FV leiden
nadroparin 3rd 40 4/7 3670 200 25
1 34 PE during COC PS def. type I/hetzg
FV leiden
– 1st 40 4/7 4330 300 20
2 30 Idiopathic DVT Hetzg FV leiden tinzaparin 2nd 38 6/7 3450 700 > 12
3 30 Recurrent fetal loss No nadroparin 2nd 38 2/7 3570 1200* 48
3 32 Recurrent fetal loss No – 1st 39 0/7 3975 500 17
4 30 CVT during COC No nadroparin/
VKA
2nd 42 0/7 3929 2000 > 12
5 30 DVT during COC No nadroparin/
tinzaparin
2nd 37 0/7 3070 400 22
6 32 Idiopathic DVT No nadroparin 2nd 40 3/7 3700 300 7
7 26 Idiopathic PE No nadroparin 2nd 33 5/7 1990/1795 1000 7
8 28 DVT during COC PS def.type III/hetzg
FV leiden
nadroparin 2nd 37 6/7 3110 200 9
9 33 PE during COC PS def type I nadroparin 3rd 41 1/7 3795 300 31
10 29 DVT during COC No nadroparin/
tinzaparin
2nd 42 0/7 3795 700 30
CVT, cerebral venous thrombosis; DVT, deep venous thrombosis; PE, pulmonary embolism; VKA, vitamin K antagonist; COC, combined oral
contraceptive use; PS, protein S; def, deﬁciency; FV, factor V; hetzg, heterozygous. *Atony of uterus Secondary caesarean section.
Letters to the Editor 1877
 2010 International Society on Thrombosis and Haemostasis
trimester and two patients during the 3rd trimester. All patients
were started initially on nadroparin or tinzaparin, two used
both preparations and one patient used a vitamin K antagonist
during the 2nd trimester before switching to fondaparinux (see
Table 1 for detailed information). In all cases, the indication
for switching to fondaparinux was hypersensitivity skin
reactions to LMWHs, consisting of itching, local redness or
subcutaneous inﬁltrates localized at the injection sites. Two
patients were treated during two pregnancies, both started
fondaparinux in the ﬁrst trimester of their second pregnancy.
No hypersensitivity skin reactions to fondaparinux were seen
and patients reported no other side effects. No early or late fetal
losses occurred. The median gestational age at delivery was
39 weeks (range 33 5/7–42 0/7 weeks). One patient delivered
preterm twins as a result of preterm prelabor rupture of the
membranes. The median blood loss during delivery was
450 mL (range 200–2000 mL); three patients had a greater
than 1000-mL blood loss. The patient with 2000 mL blood loss
had an atony of the uterus; she received her last injection of
fondaparinux more than 12 h before delivery. One patient had
1200 mL blood loss during a secondary caesarean section; she
received her last injection 48 h before delivery. The third
patient had 1000 mL blood loss because of atony of the uterus
and a preterm delivery of a twin; she received her last injection
7 h before delivery. None of these women with a greater than
1000-mL blood loss needed a blood transfusion. Postpartum,
4–8 h after cessation of the bleeding, these patients restarted on
fondaparinux 2.5 mg twice daily. No bleeding recurred after
restarting the drug. None of the 13 infants had congenital
abnormalities or neonatal bleeding. Their median birth weight
was 3685 g (range 1795–4330 g). No minor or major bleedings
or thromboembolic events were reported during the pregnancy
or post-partum period.
We report on all 12 pregnancies in our centre in which
fondaparinux was used during the past 6 years. These data are
derived from a prospective cohort study. We show that
fondaparinux was not associated with increased bleeding,
thromboembolic complications or fetal abnormalities.
To our knowledge, this is the largest prospective study that
reports on the use of fondaparinux during pregnancy. In
concurrence with others [6–11], we did not observe hyper-
sensitivity skin reactions using fondaparinux, although all
women had had hypersensitivity skin reactions to LMWHs.
Recurrence of hypersensitivity skin reactions when switching to
another preparation of LMWH in pregnant women is a known
phenomenon [1].
Fetal safety is an important issue when considering a new
anticoagulant therapy in pregnancy. LMWHs do not cross the
placenta, so can not cause teratogenicity or neonatal bleeding
[13–15]. A study by Dempﬂe et al. [11] demonstrated that
fondaparinux passes the placental barrier in vivo, resulting in
low measurable anti-FXa levels in umbilical cord blood. That
study described ﬁve pregnant women, in four of whom low
anti-FXa levels were measured. These levels were approxi-
mately 1/10 the concentration inmaternal plasma, which is well
below the concentration required for effective anticoagulation
[16]. Neonatal bleeding did not occur in the infants of these
women. In the ﬁfth woman, no elevated anti-FXa level was
measured, probably because she received her last injection of
fondaparinux 22 h before delivery. Based on these data,
fondaparinux has the potential to affect the fetus. In a recently
published retrospective study by Winger et al. [17], 29 women
with a history of unexplained recurrent fetal loss and infertility
using fondaparinux 2.5 mg once daily during the 1st trimester
of pregnancy were described. They reported no adverse events,
in particular no fetal abnormalities. In the 13 infants in our
study, no congenital abnormalities or bleeding occurred. Our
data are obviously limited by the size of our study, although it
is the largest prospective series reported. Of note, only two
infants were exposed during the ﬁrst trimester. A limitation of
our study is the missing anti-FXa levels in maternal and cord
blood during labor because of the possibility of passage
through the placenta and the potential side effects for mother
and child. Nevertheless, none of the children had neonatal
bleeding or fetal abnormalities.
In conclusion, we report here an alternative treatment with
fondaparinux in 12 pregnancies in 10 women who had
hypersensitivity skin reactions to LMWH. Fondaparinux did
not cause hypersensitivity skin reactions andwas not associated
with bleeding or other complications in the mother and child.
However, given the limited data, the use of fondaparinux
during the ﬁrst trimester should still be avoided.
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High rates of symptomatic and incidental thromboembolic
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The association of thromboembolism with cancer, although
known for over a century, has gained increased attention in
recent years. Thromboembolic complications include deep vein
thrombosis (DVT), pulmonary embolism (PE) and arterial
events including stroke and myocardial infarction. Cancer
patients on active treatment are particularly at risk, with a
recent study demonstrating a 47% increase in frequency in
hospitalized cancer patients receiving chemotherapy [1]. There
are signiﬁcant consequences of venous thromboembolism
(VTE) in the cancer patient, including an association with
mortality, a high risk of recurrent VTE and a paradoxically
high risk of bleeding complications [2–4]. Patients with
gastrointestinal cancers in particular have amongst the highest
rates of VTE [5,6].
One of the potential causes of the increased frequency of
VTE is the improvement in the resolution of computed
tomography (CT) technology in recent years. In the United
States, multidetector-row CT technology expanded consider-
ably in the earlier part of this decade [7]. This has led to an
increased frequency of incidentally detected thromboembolic
events. Recent analyzes have explored the implications of such
incidental events and it has been questioned whether these are
truly asymptomatic events [8]. Additionally, in a recent
retrospective analysis, 6-month mortality was similar in cancer
patients with symptomatic or asymptomatic VTE but signif-
icantly higher in comparison to cancer patients without VTE
[9]. These analyzes have focused primarily on incidental events.
Little is known about the prevalence and relative proportion of
symptomatic and incidental thromboembolic events.
The objective of the present study was to determine the
prevalence and relative proportions of incidental and symp-
tomatic thromboembolic events in high-risk cancer patients.
We conducted a retrospective analysis of a cohort of consec-
utive patients with gastrointestinal cancers undergoing active
treatment at the Gastrointestinal Cancer Program of the James
P. Wilmot Cancer Center at the University of Rochester
Medical Center from 1 July 2008 to 31 December 2008.
Primary sites of cancer considered for inclusion were esoph-
ageal, gastric including gastro-esophageal junction, liver,
biliary tract, pancreatic, small bowel, colon, rectum and anal.
Histologic subtypes included adenocarcinomas, squamous cell
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